A female staff member is interviewed by a television crew from the Afghanistan national TV station, Shamshad, outside MSF's maternity hospital in Khost, Afghanistan, 2013.
Browse the latest stories and reports on MSF from various media outlets.
HIV and tuberculosis (TB) policy adviser for Médecins Sans Frontièrs/Doctors Without Borders (MSF), Sharonnan Lynch, discusses the new guidelines issued by the World Health Organization for preventing and treating TB. View External Media.
Following the International AIDS conference, UNAIDS released a report that indicates more than half of the 36.7 million people with HIV have access to treatment for the first time. Despite this encouraging statistic, both HIV and AIDS death rates are increasing in Central Asia and Eastern Europe. NPR spoke with Doctors Without Borders/Médecins Sans Frontières (MSF) HIV and TB policy adviser, Sharonann Lynch, about the most recent HIV/AIDS trends.
New WHO guidelines for HIV treatment are a major step forward, but they will be a challenge for countries such as South Africa to implement, according to MSF's Dr. Gilles van Cutsem.
A House subcommittee held a hearing on international trade disputes with India. Most of the event was devoted to U.S. drug company Pfizer's complaints about Indian policies that have fostered the country's billion-dollar generics industry.
South Africa has made major progress in the fight against AIDS since 2001, when MSF was the only organization providing antiretroviral treatment in the country. "Adherence clubs" piloted by MSF now make treatment more accessible than ever.
Novartis AG goes to India's Supreme Court on Wednesday to seek patent protection for its blockbuster cancer drug Glivec in a case that could deliver far-reaching ramifications for multinational pharmaceutical companies operating in India.... Novartis's critics, including Médecins Sans Frontières [Doctors Without Borders], say that if the company prevails, it could set a legal precedent that allows pharmaceutical giants to patent a range of drugs in India that are now available from generic producers, including HIV medicines. That would demolish a thriving low-cost industry and lead to higher prices, not just in India, they say, but elsewhere in the developing world where India is a major exporter of drugs.
